- Home
- MNMD vs VTS Comparison
MNMD vs VTS Comparison
Compare MNMD & VTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- VTS
- Stock Information
- Founded
- MNMD 2019
- VTS 2014
- Country
- MNMD United States
- VTS United States
- Employees
- MNMD N/A
- VTS N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- VTS Oil & Gas Production
- Sector
- MNMD Health Care
- VTS Energy
- Exchange
- MNMD Nasdaq
- VTS Nasdaq
- Market Cap
- MNMD 960.2M
- VTS 895.8M
- IPO Year
- MNMD N/A
- VTS N/A
- Fundamental
- Price
- MNMD $11.01
- VTS $20.96
- Analyst Decision
- MNMD Strong Buy
- VTS Strong Buy
- Analyst Count
- MNMD 7
- VTS 4
- Target Price
- MNMD $26.71
- VTS $28.25
- AVG Volume (30 Days)
- MNMD 2.3M
- VTS 351.1K
- Earning Date
- MNMD 11-06-2025
- VTS 11-03-2025
- Dividend Yield
- MNMD N/A
- VTS 10.73%
- EPS Growth
- MNMD N/A
- VTS N/A
- EPS
- MNMD N/A
- VTS 0.56
- Revenue
- MNMD N/A
- VTS $248,169,000.00
- Revenue This Year
- MNMD N/A
- VTS $28.41
- Revenue Next Year
- MNMD N/A
- VTS N/A
- P/E Ratio
- MNMD N/A
- VTS $37.63
- Revenue Growth
- MNMD N/A
- VTS 6.73
- 52 Week Low
- MNMD $4.70
- VTS $18.90
- 52 Week High
- MNMD $14.43
- VTS $28.41
- Technical
- Relative Strength Index (RSI)
- MNMD 41.39
- VTS 34.62
- Support Level
- MNMD $12.60
- VTS $20.57
- Resistance Level
- MNMD $14.43
- VTS $21.22
- Average True Range (ATR)
- MNMD 0.84
- VTS 0.50
- MACD
- MNMD -0.30
- VTS -0.01
- Stochastic Oscillator
- MNMD 11.52
- VTS 51.60
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About VTS Vitesse Energy Inc.
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.